Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022

The Lancet Respiratory Medicine, Journal Year: 2023, Volume and Issue: 11(5), P. 439 - 452

Published: Feb. 11, 2023

Language: Английский

---

Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(5), P. e2310650 - e2310650

Published: May 3, 2023

Importance Estimates of the rate waning vaccine effectiveness (VE) against COVID-19 are key to assess population levels protection and future needs for booster doses face resurgence epidemic waves. Objective To quantify progressive VE associated with Delta Omicron variants SARS-CoV-2 by number received doses. Data Sources PubMed Web Science were searched from databases’ inception October 19, 2022, as well reference lists eligible articles. Preprints included. Study Selection Selected studies this systematic review meta-analysis original articles reporting estimates over time laboratory-confirmed infection symptomatic disease. Extraction Synthesis at different points vaccination retrieved studies. A secondary data analysis was performed project any last dose administration, improving comparability across between 2 considered variants. Pooled obtained random-effects meta-analysis. Main Outcomes Measures or disease half-life vaccine-induced protection. Results total 799 149 reviews published in peer-reviewed journals 35 preprints identified. Of these, 40 included analysis. a primary cycle both lower than 20% 6 months administration. Booster restored comparable those acquired soon after administration cycle. However, 9 30% The estimated be 87 days (95% CI, 67-129 days) compared 316 240-470 Delta. Similar rates found age segments population. Conclusions Relevance These findings suggest that vaccines rapidly wanes dose. results can inform design appropriate targets timing programs.

Language: Английский

---

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

BMJ, Journal Year: 2022, Volume and Issue: unknown, P. e072141 - e072141

Published: Oct. 3, 2022

To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, age immunocompromised status.Test negative case-control study.Hospitals, emergency departments, urgent care clinics 10 US states, 17 January 2021 to 12 July 2022.893 461 (≥18 years) admitted one 261 hospitals 272 department 119 centers for covid-like illness tested SARS-CoV-2.The main outcome was waning vaccine with BNT162b2 (Pfizer-BioNTech) mRNA-1273 (Moderna) during omicron delta periods, period before dominant using logistic regression conditioned on calendar week geographic area while adjusting age, race, ethnicity, local virus circulation, status, likelihood being vaccinated.45 903 people hospital (cases) were compared 213 103 who SARS-CoV-2 (controls), 287 531 168 SARS-CoV-2. In period, requiring admission 89% (95% confidence interval 88% 90%) within two months after dose 3 but waned 66% (63% 68%) four five months. Vaccine three doses visits 83% (82% 84%) initially 46% (44% 49%) Waning evident all subgroups, including young individuals not immunocompromised; although morein immunocompromised. increased among most groups a whom this booster recommended.Effectiveness vaccination. The findings support recommendations primary series consideration additional doses.

Language: Английский

---

Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 23(2), P. 167 - 176

Published: Oct. 18, 2022

Language: Английский

---

Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(2), P. e73 - e74

Published: Jan. 5, 2024

Language: Английский

---

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: June 28, 2022

We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers compare the immunogenicity reactogenicity 2-dose BNT162b2 CoronaVac in healthy adolescents as primary objectives. One-dose BNT162b2, recommended some localities for risk reduction myocarditis, is also assessed. Antibodies T cell immune responses are non-inferior or similar receiving 2 doses (BB, N = 116) (CC, 123) versus adults after same vaccine 147; CC, 141) but not 1-dose (B, 116). CC induces SARS-CoV-2 C-terminal domain seropositivity higher proportion than adults. Adverse reactions mostly mild both vaccines more frequent BNT162b2. find S, neutralising, avidity Fc receptor-binding BB induction strong S-specific cells by vaccines, addition N- M-specific induced possibly implying differential durability cross-variant protection CoronaVac, most used worldwide. Our results support use adolescents.

Language: Английский

---

Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study

PLoS Medicine, Journal Year: 2022, Volume and Issue: 19(11), P. e1004037 - e1004037

Published: Nov. 22, 2022

Individuals with a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection have moderate to high degree of protection against reinfection, though seemingly less so when the Omicron variant SARS-CoV-2 started circulate. The aim this study was evaluate vaccine effectiveness (VE) Disease 2019 (COVID-19)-related hospitalization, and COVID-19-related death, in individuals infection, assess effect time since vaccination during periods different dominant variants.This used nationwide cohort design including all confirmed who were alive, residing Denmark between 1 January 2020 31 2022. Using Danish registries, we obtained information on infections, COVID-19 vaccination, age, sex, comorbidity, staying at hospital, country origin. population included infection. Estimates VE reinfection 95% confidence intervals (CIs) calculated using Poisson regression model adjusted for origin, calendar time, test incidence Cox model. estimates separately three variants (Alpha (B.1.1.7), Delta (B.1.617.2), or (B.1.1.529)) by unvaccinated as reference. In total, 148,527 person-years 44,192 infections analysis regarding reinfections. comprised 209,814 infected before Alpha period, 292,978 245,530 period. Of these, 40,281 had completed their primary series period (19.2%), 190,026 (64.9%), 158,563 (64.6%). following any type administered Denmark, peaked 71% (95% CI: -Inf 100%) 104 days more after 94% 92% 96%) 14 43 60% 58% 62%) Waning immunity observed most pronounced Due too few events, it not possible estimate hospitalization death. Study limitations include potentially undetected reinfections, differences health-seeking behavior, risk behavior compared groups.This shows that previously individuals, completing associated significant no vaccination. Even seems protect lesser variant, these findings are public health relevance they show still benefit from periods.

Language: Английский

---

A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 224 - 224

Published: Jan. 19, 2023

Real-world data on the effectiveness of COVID-19 vaccines against Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate real-world and durability protection conferred by primary course booster confirmed infection, severe outcomes. We systematically searched literature up 1 August 2022. Meta-analysis was performed with DerSimonian-Laird random-effects model estimate pooled vaccine (VE). Overall, 28 studies were included representing 11 million individuals. The VE infection 20.4% (95%CI: 12.1–28.7%) 23.4% 13.5–33.3%) symptomatic variation based type age groups. sharply declined from 28.1% 19.1–37.1%) at three months 3.9% −24.8–32.7%) six months. Similar trends observed for infection. A dose restored 51.1% 43.8–58.3%) 57.3% 54.0–60.5%) within months; however, this waned 32.8% 16.8–48.7%) following 63.6% 57.5–69.7%) months, decreased 49% 35.7–63.4%) increased 86% after first or second dose.

Language: Английский

---

Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study

The Lancet Infectious Diseases, Journal Year: 2023, Volume and Issue: 23(12), P. 1343 - 1348

Published: Aug. 2, 2023

Language: Английский

---

The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment- a meeting report

Biologicals, Journal Year: 2024, Volume and Issue: 85, P. 101750 - 101750

Published: Feb. 1, 2024

The COVID-19 pandemic underscored the need for rapid evidence generation to inform public health decisions beyond limitations of conventional clinical trials. This report summarises presentations and discussions from a conference on role Real-World Evidence (RWE) in expediting vaccine deployment. Attended by regulatory bodies, entities, industry experts, gathering was collaborative exchange experiences recommendations leveraging RWE proved instrumental refining decision-making processes optimise dosing regimens, enhance guidance target populations, steer vaccination strategies against emerging variants. Participants felt that successfully integrated into lifecycle management, encompassing boosters safety considerations. However, challenges emerged, prompting call improvements data quality, standardisation, availability, acknowledging variability potential inaccuracies across diverse healthcare systems. Regulatory transparency should also be prioritised foster trust, improved collaborations with governments are needed streamline collection navigate privacy regulations. Moreover, building sustaining resources, expertise, infrastructure LMICs emerged as imperative RWE-generating capabilities. Continued stakeholder collaboration securing adequate funding vital pillars advancing use shaping responsive effective strategies.

Language: Английский

---